Shares of Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $16.13, but opened at $16.88. Rapport Therapeutics shares last traded at $15.98, with a volume of 2,967 shares.
Rapport Therapeutics Price Performance
The stock's 50 day simple moving average is $16.89 and its 200 day simple moving average is $20.19.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its stake in shares of Rapport Therapeutics by 38.9% during the 4th quarter. Wells Fargo & Company MN now owns 4,824 shares of the company's stock worth $86,000 after buying an additional 1,352 shares in the last quarter. Values First Advisors Inc. purchased a new position in shares of Rapport Therapeutics during the 3rd quarter worth $31,000. BNP Paribas Financial Markets acquired a new stake in Rapport Therapeutics in the 3rd quarter worth about $34,000. The Manufacturers Life Insurance Company grew its holdings in Rapport Therapeutics by 2.4% in the third quarter. The Manufacturers Life Insurance Company now owns 77,344 shares of the company's stock valued at $1,584,000 after purchasing an additional 1,828 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new stake in Rapport Therapeutics during the fourth quarter valued at about $34,000.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
See Also
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
